Table 1.

Patient Characteristics of Case Series of HIV Positive Patients with Metastatic Prostate Cancer Treated with Pembrolizumab.

Individual	Age at Prostate Cancer Diagnosis	Time to Prostate Cancer Diagnosis Post-HIV Diagnosis (years)	Prostate-specific Antigen at Start of Immunotherapy (ng/mL)	Prostate-specific Antigen Nadir on Immunotherapy(ng/mL)	RECIST v.1.1Response	Duration of Therapy (months)	Total number of Pembrolizumab cycles received
1	52	16	81	30	Partial	31	36
2	63	5	846	337	Stable	14	19